Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis
Language English Country Slovakia Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
15800710
Knihovny.cz E-resources
- MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics pathology MeSH
- Adult MeSH
- Genes, abl * MeSH
- Middle Aged MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Cell Transformation, Neoplastic * MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Proto-Oncogene Proteins c-bcr MeSH
- Proto-Oncogene Proteins biosynthesis MeSH
- Aged MeSH
- Protein-Tyrosine Kinases biosynthesis MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- BCR protein, human MeSH Browser
- Proto-Oncogene Proteins c-bcr MeSH
- Proto-Oncogene Proteins MeSH
- Protein-Tyrosine Kinases MeSH
Monitoring of BCR-ABL transcript level is widely used in chronic myeloid leukemia (CML) to follow up response to therapy. In this study we compare abilities of two quantitative RT-PCR assays to characterize the disease status in CML patients: RT-PCR quantifying the BCR-ABL transcript concentration and RT-PCR determining the BCR-ABL/BCR transcript ratio (R). We demonstrate that in non-responders only R, but not BCR-ABL, unambiguously characterizes the state of disease. Moreover, R values >1 found in all poor responders indicate lower BCR expression compared to BCR- ABL in these patients. Our results demonstrate the importance of BCR-ABL/BCR transcript ratio for the disease status and the disease prognosis characterization and suggest a possible role of the normal BCR gene expression in CML pathogenesis.
